|
The Pandemic Is Exposing the Rotten Core of Our Industrial Food System |
|
|
Written by <a href="index.php?option=com_comprofiler&task=userProfile&user=55692"><span class="small">Joseph Bullington, In These Times</span></a>
|
|
Sunday, 16 August 2020 13:00 |
|
Bullington writes: "The yellow-brown compost has been heaped into hills taller than the nearby bulldozers. The piles don't look like pigs, but that's what they are. Pigs and woodchips. "
Dream of Wild Health farm manager Jessika Greendeer gives a soil lesson to local youth July 15 in Minneapolis. (photo: Dream of Wild Health)

The Pandemic Is Exposing the Rotten Core of Our Industrial Food System
By Joseph Bullington, In These Times
16 August 20
While industrial farms have been thrown into chaos, local agriculture has proved to be a more resilient model.
he yellow-brown compost has been heaped into hills taller than the nearby bulldozers. The piles don’t look like pigs, but that’s what they are. Pigs and woodchips.
It’s mid-May and thousands of hogs have been killed and tossed in a woodchipper on this farm field in Nobles County, Minnesota. They represent but a fraction of the number of animals that have met such an end here in the third-highest hog-producing state in the country. The Minnesota Department of Agriculture said on May 6 that at least 10,000 hogs were being slaughtered and discarded every day, but no one knows the real number. The state set up the Nobles County compost site, but it’s not required to track all the killings due to a technicality, says Michael Crusan, communications director for the Minnesota Board of Animal Health. “There isn’t an animal disease issue,” he explains. “It’s just a depopulation due to market conditions.”
“Market conditions” does not mean everyone has enough to eat. In Minnesota and across the country, surging need has overwhelmed food banks. Some supermarkets limit meat purchases to prevent shelves from becoming bare. In the Minneapolis Star Tribune, one letter writer pleads for hunters to be allowed to butcher the wasted hogs, to save at least some of the meat from the woodchipper.
“Market conditions,” in this case, means meat processing plants, including the JBS pork plant in nearby Worthington, have shut down because of Covid-19 outbreaks among workers. The Worthington plant alone, which previously processed 20,000 hogs a day, has been tied to more than 700 Covid-19 cases.
The assembly line of industrial food, however, extends far beyond the processing plants. The closures have left many industrial pig farmers, who raise and ship out hogs on a regimented schedule, with nowhere to send their market-ready animals. With the next batch of hogs ready to fill the cages behind them and no other way to get the meat to hungry people, the farmers have little choice but to grind the animals into compost.
According to John Ikerd, professor emeritus of agricultural and applied economics at the University of Missouri, this failure is not a fluke of the pandemic but a weakness fundamental to the industrial food system. By extending the factory’s fixation on economic efficiency to the farm, industrialism has cut flexibility and diversity out of agriculture. Ikerd says a factory can’t slaughter 20,000 hogs a day, every day, without an inflexible schedule of when hogs are bred, born, fattened and shipped. Just as it’s more efficient to have workers each make a single repetitive cut on an assembly line than it is to have each butcher a whole hog, it’s more efficient to have a farmer raise thousands of hogs in a concentrated animal feeding operation (known as a CAFO) or only grow acres of corn than it is to raise a variety of livestock, chickens and vegetables. Despite some obvious problems, the industrial food system is a marvel of efficiency?—?until something goes wrong.
Ikerd puts it this way: “We’ve got a more operationally efficient system, but it’s a very fragile system.” Covid-19, he says, is one of many different scenarios that could bring it all crashing down.
Across the country we’ve seen chickens killed en masse, milk dumped, fields of vegetables plowed under. At the same time, we’ve seen the empty shelves, the cars lining up outside food banks.
As the pandemic has shaken the rickety scaffolding of industrial agriculture, it has woken many of us to the fragility of this system?—?and our dependence on it.
This spring, garden shops across the country sold out of seeds and seedlings. Local farmers and small-scale meat processors saw a surge of interest as people sought alternatives to industrial food. Farms that practice community-supported agriculture (CSA)?—?a model in which people buy “shares” of a farmer’s harvest at the beginning of a growing season and later receive weekly fresh food boxes?—?sold out and filled their waiting lists.
The surging interest in local food may not make up all the losses small farms are suffering, but it has been a lifeline for many. And it just might help the country make a long-term shift toward a more sustainable, more resilient and more just food system.
Shared Risk, Shared Reward
In mid-March, about a month before pork plant closures left industrial hog farmers stranded, Minnesota closed public schools—a crucial market for Open Hands Farm in Northfield, Minnesota. Instead of hogs, though, Ben Doherty and Erin Johnson were left holding more than 9,000 pounds of carrots.
Doherty and Johnson grow vegetables for local markets on their small organic farm. Carrot sales to schools account for a large share of their business, so they had to improvise. They explained their predicament on Facebook and offered 25-pound bags of carrots, direct to customers, at wholesale prices. They sold out within a day.
As the weather warmed, it remained unclear when schools would re-open, but Doherty and Johnson had to make decisions about planting. They pushed ahead with their usual crops, planning to find alternative markets if needed. To hedge their bets, they also increased their CSA offerings from 180 shares to 220.
Carrie Sedlak, executive director of the FairShare CSA Coalition based in Madison, Wis., says this “nimbleness” makes local agriculture more resilient than industrial food systems. As Covid-19 lockdowns hit, many of the coalition’s 44 member farms (scattered across Wisconsin, Minnesota, Illinois and Iowa) lost school and restaurant markets and had to lean more heavily on the CSA side of their operations.
The CSA model feels uniquely sturdy in the time of Covid-19. CSAs help small farmers, who operate on thin margins, adapt to shifting markets by putting money in their pockets upfront, when they need it most. The farmers distribute food straight to local people, who can pick up a CSA share outdoors with minimal contact. Most importantly, the model doesn’t paper over the financial risks of farming?—?it acknowledges them and asks the community to share the burden. If something goes wrong, CSA customers might receive different or fewer items than expected, but their boxes wouldn’t be empty, unlike store shelves during the pandemic.
In exchange for shouldering some of the risk, the participant enjoys a rare kind of food security. “You know the farmer and you know this person grows food locally,” Sedlak says. “It feels more secure than relying on this big, nebulous system.”
For these reasons, Sedlak thinks, CSAs have seen a surge in interest. This spring, all but the biggest farms in the coalition sold out of shares.
Crisis And Opportunity
When Virginia instituted its stay-at-home order in late March, it closed not only universities, schools and restaurants but also farmers markets, another pillar of local food systems.
“Those closures instilled a lot of panic on farms,” says Kristen Suokko, executive director of Local Food Hub in Charlottesville.
In addition to hardship, Ikerd thinks the food disruptions are creating opportunities for systemic change.
Since the pandemic hit, online grocery sales in the United States have soared. Amazon, Walmart and Target have racked up the vast majority of customers in the past year, but when it comes to selling food online, Ikerd says local producers enjoy significant advantages over food corporations. For example, local farmers can supply fresh food to local customers more efficiently than state or regional operations because they don’t have to spend nearly as much money on transportation, packaging and marketing. (In the current industrial food system, 85 cents of every dollar spent on food goes to marketing while only 15 cents goes to the farmer, according to the U.S. Department of Agriculture.) If local farmers could tap the burgeoning online market rather than battling for room in the mainstream distribution and retail systems, Ikerd says, then local producers and their customers could “totally bypass the industrial food system.”
That’s just what some local food groups have begun to do, out of necessity as much as out of a long-term vision.
Within days of Virginia’s stay-at-home order, Local Food Hub launched drive-thru markets to comply with Covid-19 regulations. Customers could order food online from a variety of local farms and pick it up twice a week.
“Demand was incredible in those first two months,” Suokko says. “Some farmers have said it was the lifeline that kept them going.”
In Wyoming, Slow Food of the Tetons found similar success when it moved its usual year-round farmers market online. Slow Food’s executive director, Scott Steen, says the market, based in Jackson Hole, offers food from 28 farms and saw as many as 200 orders in a good week.
“The online market has sold way more food than we would’ve sold at a winter farmers market,” Steen adds?—?and it’s served as an essential alternative for local farmers who lost buyers during the pandemic.
Self-organizing To Feed Each Other
Not every neighborhood, however, has a farmers market?—?or even a grocery store. Tens of millions of Americans live in food deserts, which are primarily in poor neighborhoods, rural areas and communities of color.
Shania Morris sees this lack of access to food as a kind of violence. Morris is an organizer with Soil Generation, a Black- and brown-led coalition of growers in Philadelphia that fights for food justice and food sovereignty.
“Black people are not only dying at the hands of police,” Morris says. “They are dying because of lack of access to healthy food and healthcare, and because they’re being overworked.
“Our supermarkets and our jobs systems don’t meet the needs of everyone,” Morris says. “In this community, we’re finding ways to do that outside of capitalism.” The group works to shape urban agricultural policy, increase access to land and help neighborhoods build gardens on what land they do have?—?work that’s become more urgent as people have lost income.
Enlylh King, a Soil Generation coordinator, lives communally and grows food for herself, her friends and her neighborhood. King thinks the pandemic has made people more interested in independence from oppressive systems, including the industrial food chain.
“We don’t want to get to the point where we’re so dependent on this thing that’s so far outside of ourselves that we can’t even take care of ourselves,” King says.
Morris says growing food as a means of building sovereignty is nothing new to Black communities. In 1920, almost a million farms in the United States were Black-owned—14% of all farms. But as systemic racism dispossessed Black communities, that number plunged. As of 2017, only 35,470 farms in the United States were Black-operated—1.7% of all farms.
“We’ve always been needed, we’ve always been here,” Morris says of Black growers. “Now, this moment has shown the truth of what we’ve been saying for a very long time.”
In Minneapolis, the Indigenous-led nonprofit Dream of Wild Health, which runs a 10-acre farm north of the city, partnered with other groups to deliver meals to the Twin Cities Native community during this time of crisis.
Neely Snyder, Dream of Wild Health executive director, says nonperishable food offered by many pantries?—?while meeting some immediate needs?—?is “not the healthiest stuff.” She thinks that makes her group’s mission to deliver fresh, healthy, minimally processed foods even more essential.
Every year, the farm distributes more than seven tons of vegetables and fruits by way of youth programs, farmers markets, partnerships with Indigenous chefs and its CSA-style Indigenous Food Share. This spring, as people lost jobs and access to food, Dream of Wild Health planted earlier than usual in anticipation of increased need, says farm manager Jessika Greendeer. Normally, parts of the farm lie fallow, Greendeer says, but this year they planted every available inch with summer squash, cucumbers, corn, tomatoes, winter squash and beans.
Dream of Wild Health makes its food available at less than the “normal farmers market price,” Snyder says. Other local-food nonprofits offer similar programs to make local food more accessible. The FairShare CSA coalition, for example, will pay for half a CSA share for low-income people. Slow Food of the Tetons distributes a localized version of food stamps, and unlike the federal SNAP program, it’s available to undocumented people.
Suokko says this approach has limits. “We’ve been hugely effective at making local food available through philanthropy,” she says. “We’ve not been successful at making it so, if you’re a low-income person, you can go to a local store and buy a local tomato.”
“The Transition Is Already Well Underway”
For local food systems to overgrow the fringes and reclaim a central role in how we eat, we need more farms growing diverse crops and raising animals to feed people who live in their area. And the food needs to be accessible and affordable.
Unfortunately, Sedlak says, “Capitalism tends toward consolidation, not diversification.”
Capitalism is aided by federal farm policy, which funnels assistance and subsidies almost exclusively to big, mono-crop commodity farms. Diversified farms that produce vegetables and fruits, known to the Department of Agriculture as “specialty crops,” do not qualify for federal subsidies or crop insurance.
“The very fact that fruits and vegetables are labeled ‘specialty crops’ in USDA parlance tells you everything,” Suokko says. Only 2% of U.S. farmland grows fruits and vegetables while almost 60% grows commodities like soybeans and corn. Some of those sprawling fields will eventually have to be restored and diversified, unless we want to plow what little is left of the American grasslands. (Which isn’t much: In Illinois, for example, only 2,500 acres of prairie remain, of an original 22 million.)
North of Minneapolis, Dream of Wild Health is scaling up. Before the state’s lockdown order took effect, the group purchased an additional 20-acre farm. Greendeer and her team are busy restoring the land, which has been in mono-crop corn rotations the past two seasons. She hopes it will be ready for planting in 2021.
According to Ikerd, the federal farm support system should stop subsidizing the industrial food system and instead support small, diversified farms, along with those conventional farmers who are able to transition. “If,” he says, “they still remember how to manage a farm rather than a biological factory.” We are also, Ikerd says, going to have to “grow a lot of new farmers” and give them access to land.
According to Sedlak, the main barriers that keep people from farming are a lack of access to affordable land and a lack of capital to start. Not all farmers have access to grants and donations, which is how Dream of Wild Health, for example, funded its expansion. The need is particularly great in Black communities, Indigenous communities and others that have been systematically deprived of access to land and sovereignty over their food.
We have become so dependent on the industrial food system that it’s difficult to imagine a world without it, but Ikerd takes a more optimistic view. “The transition to the new local, sustainable food systems is already well underway,” he says. “We just need government policies and public institutions to support it.”

|
|
FOCUS: Who Won the Battle of Portland? |
|
|
Written by <a href="index.php?option=com_comprofiler&task=userProfile&user=51527"><span class="small">Tim Dickinson, Rolling Stone</span></a>
|
|
Sunday, 16 August 2020 11:59 |
|
Dickinson writes: "The violent occupation of an American city - over the objection of state and local elected leaders - by irregular federal forces, in league with the city's reactionary police, seemed for a vertiginous moment like it could mark America's free fall into fascism. But everyday residents of Portland rose in resistance, including suburban moms who put their bodies between the feds and younger BLM protesters."
Federal officers use chemical irritants and crowd control munitions to disperse Black Lives Matter protesters outside the Mark O. Hatfield United States Courthouse on Wednesday, July 22, 2020, in Portland, Ore. (photo: Noah Berger/AP)

Who Won the Battle of Portland?
By Tim Dickinson, Rolling Stone
16 August 20
How the liberal city’s uprising turned back Trump’s authoritarian revival of ‘law and order’ politics
ummer morning light, the federal courthouse is eerily calm. The perimeter of the Mark O. Hatfield building, a 16-story high-rise occupying a block of downtown Portland, Oregon, emerged in July as the front line for nightly assaults by federal agents against Black Lives Matter protesters, whom President Trump labeled “sick and deranged Anarchists & Agitators.”
The pretext for the incursion of federal forces into Portland — where unidentified armed agents in fatigues snatched protesters and shoved them into unmarked vans — was defacement of this courthouse. But the criminal mischief against the building was modest, according to the government’s own reckoning: “in excess of $50,000” — or roughly the cost of a used Winnebago.
The courthouse only gathered more spray paint after the feds arrived. “Send home Trump’s piglets,” reads one graffito. “Fuck DHS,” reads another, targeting the Department of Homeland Security, which has resembled a tin-pot interior ministry while carrying out Trump’s “Operation Diligent Valor.”
The violent occupation of an American city — over the objection of state and local elected leaders — by irregular federal forces, in league with the city’s reactionary police, seemed for a vertiginous moment like it could mark America’s free fall into fascism. But everyday residents of Portland rose in resistance, including suburban moms who put their bodies between the feds and younger BLM protesters. The government response was extreme. Federal agents shot nonviolent protesters and reporters in their faces with riot munitions, fracturing the skull of one. Trump’s little green men unleashed cloud banks of tear gas — a munition banned by the Geneva Convention — at one point turning an exterminator’s fogger on Americans exercising their First Amendment rights.
The grotesque optics generated a nationwide outcry, giving Gov. Kate Brown the upper hand to broker the withdrawal of what she blasted as an unaccountable “occupying force.” The front page of the French newspaper Le Monde on August 1st captured the embarrassing setback for the 45th president: “Trump, Grand Perdant de la Bataille de Portland” (“Trump, Big Loser in the Battle of Portland”).
But there was a method to the madness that unfolded outside this federal courthouse, a crackdown the president threatened to expand to Chicago and other American cities. The nation had been ravaged by Trump’s inability to lead: More than 150,000 Americans were dead from a pandemic that competent nations had subdued; 25 million Americans were unemployed, and the economy contracted by a third. Seeking a Hail Mary for his re-election campaign, Trump pulled one of the ugliest, but most reliable, strategies from the Republican playbook: “law and order.” The racially coded message catapulted Richard Nixon to victory in 1968; formed a cornerstone of Ronald Reagan’s presidency; and keyed George H.W. Bush’s implausible comeback victory in 1988. By playing to white America’s fears of urban violence and black empowerment, politicians have long won elections, and justified expansions of America’s carceral state.
In the Oval Office in July, Trump said the quiet part out loud, describing the deployment of federal forces in an explicit campaign context. The rage seen in the streets of Portland, Trump claimed, would overwhelm an America not governed by his heavy hand: “If Biden got in, that would be true for the country.” He added, as though his own administration had not delivered America to the gates, “The whole country would go to hell.”
Commissioned by President Lyndon Johnson in the wake of rioting in Newark, Watts, and Detroit, the Kerner Report established a high-water mark in the federal response to the civil rights movement. Written in 1968, it remains “woke” even by 2020 standards, attributing black uprisings to the rot of white bigotry and systemic racism: “What white Americans have never fully understood — but what the Negro can never forget — is that white society is deeply implicated in the ghetto. White institutions created it, white institutions maintain it, and white society condones it.”
The report called on America to “make good on the promises of American democracy to all citizens” by mounting “programs on a scale equal to the dimension of the problem.” Nixon had a different idea: The solution to racial violence would not be found in programs to remedy structural disadvantage, he said, but in heightened policing to beat down unrest.
Nixon’s 1968 campaign hinged on what a young strategist identified as the “law and order/Negro socio-economic revolution syndrome.” Nixon appropriated the phrase “law and order” from his segregationist rival, Alabama Gov. George Wallace, who had directed the violence against marchers in Selma.
Nixon’s dark insight was to throw a cloak of righteousness over resentful whites, while casting law enforcement as the protectors of their American dream. In his 1968 convention speech, Nixon evoked “cities enveloped in smoke and flame” and “sirens in the night,” before calling on the country to heed “the quiet voice” of the “forgotten Americans.” In an infamous television ad produced by future Fox News founder Roger Ailes, Nixon presented “law and order” in the language of protest. “Let us recognize that the first civil right of every American is to be free from domestic violence,” Nixon intoned over images of tumult in the streets. “So I pledge to you that we shall have order in the United States.”
Nixon’s win marked a dead-end for the civil rights movement, and the launch of the wars on crime and drugs that have squandered trillions of dollars over-policing and incarcerating black Americans. Across the decades, Republicans continued to wield “law and order” as a truncheon against Democrats. Pertinent to Trump’s present circumstance, George H.W. Bush showed that provoking white fear of black crime could reverse the electoral tides.
In July 1988, Massachusetts Gov. Michael Dukakis had opened up a 17-point advantage over Bush. The Bush team then uncorked one of the most racist attack ads in American politics. A gleeful Ailes, one of Bush’s top strategists, told reporters, “The only question is whether we depict Willie Horton with a knife in his hand or without it.”
Horton had escaped from a rehabilitation program that gave weekend furloughs to Massachusetts prisoners. The ad featured a grainy image of Horton towering menacingly over a white cop; it described how he’d “kidnapped a young couple, stabbing the man and repeatedly raping his girlfriend.” The ad mined America’s deep sexual psychosis about the danger of black men to white women. Bush didn’t use the phrase “law and order,” says Kevin Kruse, a Princeton historian, “but he tapped into the same authoritarian politics, the same kind of racial panic.” Dukakis won just 10 states.
The crucible of 9/11 transformed the GOP’s “law and order” politics into “tough on terror” politics. In 2002, George W. Bush undertook a massive restructuring of government, bringing more than a dozen law-enforcement agencies under the umbrella of the new Department of Homeland Security. Civil libertarians warned the de facto interior ministry would be ripe for authoritarian abuse. Former California Sen. Barbara Boxer now insists they were right: “I never imagined that a president would use [DHS],” she writes, “to terrorize our own citizens in our own country.”
The Muslim community would like a word. “It shouldn’t surprise anybody that an entity like DHS has been engaging in nefarious activity,” says Zakir Khan, board chair for the Oregon chapter of the Council on American-Islamic Relations, who describes the personal trauma of “being harassed, being interrogated” by DHS agents for having a name they find suspicious. He blames Congress: “There’s never been a critical re-examining of that. Ever since 9/11, it’s been one blank check after another.”
Donald J. Trump came of age with Nixon. And he was familiar with white grievance. In the 1970s, his family business was charged by the Justice Department for violating the Fair Housing Act of 1968 by not renting to black tenants. Trump has also long decried urban violence in reactionary terms. In 1989, he took out a full-page newspaper ad demanding the death penalty for the “Central Park Five,” a group of young men falsely accused of raping a jogger: “I want them to understand our anger. I want them to be afraid,” Trump wrote. “Criminals must be told that CIVIL LIBERTIES END WHEN AN ATTACK ON OUR SAFETY BEGINS!”
In his 2016 presidential run, advised by Ailes, who’d been forced out of Fox News due to sexual abuse, Trump revived Nixonian appeals to the “silent majority.” In 2020, he’s continuing to blast the same racist dog whistles, promising “people living their Suburban Lifestyle Dream” that he’ll make sure they’re not “financially hurt by having low-income housing” in their neighborhoods. “Donald Trump is a prisoner of the past,” says Stuart Stevens, Mitt Romney’s 2012 campaign strategist and author of It Was All a Lie, an examination of the GOP’s professed values. “The guy is just frozen in, like, 1977, out on the Queens Expressway.”
Kruse says 2020 Trump has overstepped Nixon and is channeling pure Wallace, the brutal segregationist. “There are clear echoes of Wallace in ’68” he says, including Trump’s choice of targets — substituting Antifa and BLM for hippies and civil rights demonstrators — and an identical “macho posturing about how he would crack down on them.”
When Trump deployed federal agents to Portland in mid-July, the objective was not to defuse tensions in the restive city but to inflame them. “It was an escalation on top of escalation,” says Kelly Simon, interim legal director of the ACLU in Oregon. At the president’s direction, DHS deployed agents from an alphabet soup of federal agencies to Portland, including members of BORTAC, the border patrol’s SWAT team, despite an internal memo warning that these agents were not trained in crowd control. Repeating a tactic that local police had admitted was a mistake, DHS erected a fence between the courthouse and the street, creating a front line for battle.
A contingent of Portland protesters has long sought to provoke law-enforcement brutality to underscore how America is transforming into a police state. Trump appeared only too eager to prove them right. Initially, Fox News gave Trump the agitprop he craved. Sean Hannity painted Portland as a “war zone.” Tucker Carlson described a city under siege by “the armed wing of the Democratic Party.” Laura Ingraham warned that “if Biden is elected, Antifa will see it as their victory” and that “holy hell will be unleashed from coast to coast.” To suggest that Trump’s “law and order” messaging was tailor-made for Fox News would be to invert the matter. The network was built by Ailes to inject just this kind of authoritarian trope into America’s political bloodstream.
But Trump overplayed his hand. Protesters like Mac Smiff, a prominent black activist in Portland, described how the feds ratcheted up the violence. “We came out here dressed in T-shirts, using hula hoops and stuff — they started gassing us,” he said. “So we came back with respirators — they started shooting us. So we came back with vests — they started aiming for the head. So we started wearing helmets. And now they call us terrorists. Who’s escalating this? It’s not us.”
Adopting tactics from pro-democracy activists in Hong Kong, protesters used umbrellas and homemade shields to guard themselves from projectiles, and shined laser pointers to disrupt the aim of agents. In federal court, Justice Department lawyers underscored injuries incurred by federal agents, including one hit by “a protester wielding a two-pound sledgehammer” and another “hit in the leg with a marble or ball bearing” from a slingshot. But the response by the federal agents was rarely directed at specific wrongdoers; the intention was mass punishment. In a nightly ritual, the feds burst out of the courthouse to scatter the crowd into the streets of downtown. An investigation by Physicians for Human Rights decried the “disproportionate, excessive, and indiscriminate,” federal violence, “that caused severe injury to innocent civilians.”
Public outrage grew with video of nonviolent protesters being abducted by camouflaged feds. (Attorney General Bill Barr would insist those snatched were suspected of having shined laser pointers at agents.) “I was afraid for my life,” Mark Pettibone, one of those captured, later told Congress. “They didn’t tell me who they were with or why I was being detained. They simply forced me into the back of the van.” The sweeps brought condemnation from the GOP’s libertarian wing, and the nation’s first Homeland Security chief, Tom Ridge, who blasted Trump for using DHS as a “personal militia.”
A general uprising by citizens of Portland soon gave Trump more than he bargained for. “What they didn’t realize is this is a city of resistance,” says Khan. First, a towering former Navy officer, 53-year-old Chris David, confronted federal marshals about their duty to the Constitution. The camouflaged agents maced him in the face and beat him with batons, shattering his hand. Then, a bloc of largely white moms in yellow T-shirts and bike helmets descended on the front lines, locking arms at the feds’ fence. “Going to join the Wall of Moms,” a mother named Tara Russell posted on Facebook on July 19th. “I really hope I don’t get tear-gassed, but I can’t sit at home anymore and watch these brave young people get beaten and rounded up by the Federal Secret Police.”
Protesters whom the president had marginalized as America-hating radicals now looked like the suburban housewives he wanted to spook into voting for him. In singsong unison, they taunted the federal agents: “Hands up, please don’t shoot me.” Sen. Ron Wyden, an Oregon Democrat, blasted Trump: “Only a coward would try to convince the entire country that these people are violent anarchists.” After attending to his injuries, Chris David helped organize a Wall of Vets, which stood with a Wall of Dads, equipped with leaf blowers to combat tear gas.
Even Fox News condemned the president’s “overreach” in Portland. Trump lashed out. “The Lamestream Media, including @FoxNews, which has really checked out, is refusing to show what is REALLY going on in Portland,” he tweeted. “They want the American public to believe that these are just some wonderful protesters, not radical left ANARCHISTS!” Resorting to conspiracy theory, he raged, “The line of innocent ‘mothers’ were a scam.”
That same day, Kristen Jessie-Uyanik, a 41-year-old Portland mother of three (and, full disclosure, a buddy of mine from neighborhood barbecues), was shot between the eyes with riot munition. Centering the suffering of black Americans over her own discomfort, she encouraged her friends to “vote like you could get shot in the face for stepping out and speaking up.”
With the president on the defensive, Biden pressed his advantage, blasting Trump for seeking to “stoke division and chaos” in Portland. “This isn’t about law and order,” Biden added. “It’s about a political strategy to revive a failing campaign.”
Trump’s embrace of “law and order” politics was always a sign of desperation, argues Stevens, the GOP strategist. “In moments of stress, politicians try to do what they’re comfortable doing,” he says, comparing Trump to a fastball pitcher who hits a tight spot and tries to get out of it by bringing high heat. “Trump is the candidate of division. Trump is a candidate of anger. Trump is all about racial antagonism. So what’s he going to do when he’s in a jam? He’s going to try to create it. Try to make the country care about it. And I just don’t see any evidence it’s working.” In a recent poll, more suburban dwellers predict the nation will be less safe under a second Trump administration (48 percent) than under a Biden one (37 percent).
With no letup by protesters on the ground and Barr being raked over the coals for partisan deployment of federal law enforcement, the president seized on an offer presented by Gov. Brown for state troopers to secure the courthouse, giving Trump cover to withdraw his ad hoc army from the fence. Trump talked tough on the way out, blasting Portland as a “beehive of terrorists” and insisting his intervention had saved the city from being “burned and beaten to the ground.”
This is absurd, of course. The post-apocalyptic scenes of violence had played out within a perimeter of just a few blocks. A Starbucks near the courthouse remained bustling through the protests. And as the feds left town, the streets downtown returned to civility, with protesters making speeches in defense of black lives and celebrating the federal withdrawal. In a sign of Portlandia’s healing, a white guy on an electric unicycle turned victory laps while juggling bowling pins.
Was Portland a prelude for a broader federal crackdown in U.S. cities? In July, Trump sent federal law-enforcement teams to Chicago, Albuquerque, Cleveland, Detroit, and Milwaukee in a deployment called “Operation LeGend,” shamelessly named for a black preschooler killed by gun violence. Tapping into white racial fear that girds the “law and order” platform, the president argued without evidence that BLM protests “to shut down policing” had sparked an “explosion of shootings, killings, murders, and heinous crimes of violence.” Earl Blumenauer, who represents Portland in Congress, insists Trump’s “Gestapo-like tactics” have been “a dress rehearsal for other communities around the country.”
Kruse, the Princeton historian, doesn’t rule out a darker authoritarian purpose, but argues the TV-obsessed president’s play in Portland was likely propagandistic. The campaign, he argues, wants to cast Trump as the great patriot — cue images from his rally at Mount Rushmore — standing against anarchy in the streets — cue tear gas in Portland. “They’ve got the B-roll footage for campaign ads now,” with the intent, he says, to “scare middle-class white people back into their ranks.”
But the president has fundamentally misread the success of “law and order” politics, Kruse argues, which is effective as an insurgent strategy but can backfire on incumbents, whom voters blame when danger and chaos erupt in the streets. “Trump is trying to use something that only works if you’re not the one currently in charge,” Kruse insists.
Historian Rick Perlstein is the author of Nixonland: The Rise of a President and the Fracturing of America. He insists the political well Trump is trying to tap has run dry. “The obsession with the supposed lessons of Nixon and ‘law and order’ politics,” he says, “is very ‘OK boomer.’”
If Republicans are trying to make this election about “the mob,” it’s because “they’re lost,” says Stevens. “They were going to run on the economy. Well, they can’t do that. And they were going to run against socialists,” and then Biden won the nomination. “Even their nickname, ‘Sleepy Joe Biden’ — is that supposed to scare women and children?” Worse for Trump, the attempt to shift the narrative to “law and order” is likely only to anger centrist voters who see him shirking his responsibility for the crises he’s bungled. “Covid-19 and the economy is what this race is about,” Stevens says. “And all the king’s men and all the king’s horses can’t make it about something else.”

|
|
|
Big Pharma's Covid-19 Profiteers |
|
|
Written by <a href="index.php?option=com_comprofiler&task=userProfile&user=51548"><span class="small">Matt Taibbi, Rolling Stone</span></a>
|
|
Sunday, 16 August 2020 08:18 |
|
Taibbi writes: "In a breezy open letter, Daniel O'Day explained how much his company planned on charging for a course of remdesivir, one of many possible treatments for Covid-19."
A vial of remdesivir at a Gilead manufacturing site in the United States. (photo: Gilead Sciences/AP)

Big Pharma's Covid-19 Profiteers
By Matt Taibbi, Rolling Stone
16 August 20
How the race to develop treatments and a vaccine will create a historic windfall for the industry — and everyone else will pay the price
n June 29th, 2020, while America remained transfixed by anti-police protests, the chairman and CEO of the pharmaceutical company Gilead issued a much-anticipated announcement. In a breezy open letter, Daniel O’Day explained how much his company planned on charging for a course of remdesivir, one of many possible treatments for \Covid-19\. “In the weeks since we learned of remdesivir’s potential against Covid-19, one topic has attracted more speculation than any other: what price we might set for the medicine,” O’Day wrote, before plunging into a masterpiece of corporate doublespeak.
The CEO noted a study by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, showing that Covid-19 patients taking remdesivir recovered after 11 days, compared with 15 days for placebo takers. In the U.S., he wrote, “earlier hospital discharge would result in hospital savings of approximately $12,000 per patient.”
The hilarious implication seemed to be that by shortening hospital stays by four days on average, remdesivir was worth $48,000 a dose. That O’Day might come to such a conclusion was not outlandish. Gilead became infamous a few years ago for charging $84,000 per course of treatment for Sovaldi, a “groundbreaking” hepatitis-C drug. The company’s policies for pricing have more than once prompted congressional hearings, as in the case of Truvada, a drug to combat HIV transmission that was developed in part with the aid of government grants and that earned Gilead more than $30 billion in revenue. Would they try something similar at a time of unprecedented medical terror with one of the few available Covid-19 treatments?
No, as it turned out. Although “we can see the value that remdesivir provides” — i.e., we could have charged $48,000 per dose — Day wrote, “we have decided to price remdesivir well below this value.” He went on to say that to “ensure broad and equitable access at a time of urgent global need,” Gilead had generously decided to place the price for remdesivir at a measly $3,120 per patient.
Investors were bummed. Gilead even undercut the prediction of the Institute for Clinical and Economic Review (ICER), a watchdog that calculated a fair price for remdesivir at $4,500 per course of treatment. When Gilead announced a price below that level, it caused a tremor on Wall Street, as its share price fell. The company had already offended the Gods of Capitalism by donating hundreds of thousands of existing doses of remdesivir to the government. What self-respecting American corporation voluntarily undermines its own market?
Not Gilead, as it turns out, and really, not any pharmaceutical company. What Americans need to understand about the race to find vaccines and treatments for Covid-19 is that in the U.S., even when companies appear to downshift from maximum greed levels — and it’s not at all clear they’ve done this with coronavirus treatments — the production of pharmaceutical drugs is still a nearly riskless, subsidy-laden scam.
Americans reacted in horror five years ago when a self-satisfied shark of an executive named Martin Shkreli, a.k.a. the “Pharma Bro,” helped his company, Turing Pharmaceuticals, raise the price of lifesaving toxoplasmosis drug Daraprim from $13.50 to $750 per pill. Shkreli, who smirked throughout congressional testimony and tweeted that lawmakers were “imbeciles,” was held up as a uniquely smug exemplar of corporate evil. On some level, though, he was right to roll his eyes at all the public outrage. Although he was convicted on unrelated corruption charges, little about his specific attitudes toward drug pricing was unusual. Really, the whole industry is one big Shkreli, and Covid-19 — a highly contagious virus with unique properties that may require generations of vaccinations and booster shots — looms now as the ultimate cash cow for lesser-known Pharma Bros.
“The power of the industry combined with fear is driving extraordinary spending,” says U.S. Rep. Lloyd Doggett (D-Texas), who has been an outspoken and sometimes lonely voice warning about pandemic profiteering. “It all suggests rosy times ahead for the pharmaceutical industry.”
Doggett cautions that the rush for a cure is already padding the bottom lines of drug companies. Take the example of remdesivir, which he describes as having been “pulled off the scrap heap” to become a major revenue-driver. Having failed to be approved as a treatment for hepatitis and Ebola, it is now one of the most in-demand products in the world, and its price isn’t quite so low as Gilead claims.
For one thing, ICER reported it costs just $10 of raw materials to make each dose of remdesivir. Generic-drug producers in Bangladesh and India were already making a version of it, and their price per course of treatment was $600. Meanwhile, Gilead’s own price for governments around the world — the price it settled on for everyone except American private insurers — was $2,340 per treatment.
Moreover, ICER’s assessment of remdesivir’s price relied significantly on the idea that it would actually help save the lives of Covid-19 sufferers. “If the drug doesn’t impact mortality, and only shortens recovery time,” says Dave Whitrap of ICER, “we figure a course of treatment is worth about $310.”
To recap: Gilead, a company with a market capitalization of more than $90 billion, making it bigger than Goldman Sachs, develops an antiviral drug with the help of $99 million in American government grant money. Though the drug may cost as little as $10 per dose to make, and is being produced generically in Bangladesh at about a fifth of the list price, and costs about a third less in Europe than it does in the U.S., Gilead ended up selling hundreds of thousands of doses at the maximum conceivable level, i.e., the American private-insurance price — which, incidentally, might be about 10 times what it’s worth, given its actual medical impact.
But almost no one cared. A day after the remdesivir price was announced, Donald Trump bought 500,000 doses through September, basically the entire world supply of the drug. There were a few stories in the American press quoting Europeans who seemed startled by the selfishness of the act. “Imagine if this was a vaccine?” Liverpool University’s Dr. Andrew Hill wondered. Mostly, however, the reaction to the U.S. hoarding one of just two drugs shown to have positive effects in treating a civilization-imperiling disease (the other is the steroid dexamethasone) was muted.
Why? As articulated by Trump press secretary Kayleigh McEnany, no sick person will ever see anything like a bill for the real cost of the drug. “The hospitals have to eat the cost of treatment use,” McEnany said. “The patient will not see the cost.”
This sounds great on the surface, but of course, Americans, through their tax dollars, will pay for treatments like remdesivir and for potential vaccines. Recent House and Senate emergency-spending bills allocate as much as $20 billion or more for vaccine development, and another $6 billion for manufacturing and distribution. “The public will pay for much research and manufacturing,” says Doggett. “Only the profits will be privatized.”
Still, because individuals won’t be handed physical bills for pills or shots, nobody balks at prices companies set, if they even know what they are. With remdesivir, “nobody in the Trump administration complained” about price, says Gerald Posner, author of Pharma: Greed, Lies, and the Poisoning of America. “Just as nobody in a Biden administration likely would have complained. Does anybody care?”
It’s surprising, or maybe it isn’t, that all of this is going on during a period of intense political protest. For as much as America is going through changes, many of the dumbest aspects of our political system have remained impervious to reform. There was political will to change the formula for Big Pharma in the early Nineties and in the Obama years, and revolution is in the air now. Just likely not enough to bring drug prices down to a reasonable level.
Profiteering over the coronavirus pandemic is still in the larval stage. The average news reader has heard some enraging stories — a man busted for a $45 million scheme to defraud New York City through phony PPE sales, another arrested for hoarding 192,000 N95 respirator masks and 598,000 medical gloves, a third caught trying to bilk the VA out of $750 million — but the giant-scale gouging will take place later. And it will all be legal.
Soon enough, the infected and uninfected alike will pay any price to try to stave off illness through vaccines and cocktails of expensive treatments. It is an unprecedented profiteering opportunity, because most everyone on Earth is destined to become a customer of some kind — in fact, the United States is already a massive buyer of Covid-19 treatments despite no evidence of efficacy. “We’re in the extraordinary position of spending billions on vaccines before we know if they work,” says Doggett.
Some of the rush to spend money on treatments is driven by a perhaps-unrealistic expectation that vaccines will be available soon, or at all. Dr. Robert Gallo, co-founder and international scientific adviser of the Global Virus Network and one of the world’s leading virologists — he is the co-discoverer of HIV and the developer of the HIV blood test, among other things — worries that the unique characteristics of Covid-19 will make it hard for any traditional vaccine to have “durability.”
“You look at the structure of the proteins, and it’s a lot like HIV, because of its glycan shields,” he says, referring to sugars that protect viruses from antibodies. “Antibodies that are glycosylated in this way do not last.” Because of this, Gallo says, he worries that companies might be tempted to declare victory prematurely. He warns that people who put timetables on when treatments might be available — Trump often says things like, “We’re very close,” and press observers like Politico have warned that the administration is sitting on an “October vaccine surprise” — are almost always being disingenuous. “I’ve always said, you don’t have a vaccine until you have one, until you’re sure it works.”
Still, there’s widespread expectation that vaccines are coming — we’ve heard reports about vaccines like AstraZeneca’s AZD1222 supposedly producing good results in trials — and an observer looking on the surface level might conclude that Big Pharma in this crisis is breaking long-standing patterns of exploitation. After all, several of the biggest drugmakers have made public pledges to produce vaccines at cost, including Johnson & Johnson and AstraZeneca. “We’ll do it at no profit,” AstraZeneca CEO Pascal Soriot said. “This is what a successful, healthy pharmaceutical industry can do.”
The problem with these pledges is nobody knows what they mean. In the case of Johnson & Johnson, the company promised to produce vaccines at cost “for the duration of the emergency.” When Doggett and his staff asked what this means, they got no answer. Nor is there any transparency about what terms like “cost” mean, or how the billions allocated for research are being spent.
Add the unique arc of the Covid-19 story — which may require decades of intense, ongoing investment — and gestures like the ones made by Johnson & Johnson and AstraZeneca begin to give off an ominous odor. “You can put about as much faith in their promises as you can in the pitch of any salesperson,” says Doggett.
The Covid-19 disaster will rely significantly upon these corporate drugmakers to not only come up with cures and treatments, but to also create a manageable price for people around the world, since the pandemic won’t be stopped unless the whole world gets treated. “Is Big Pharma going to do the right thing?” asks Dana Gill, U.S. policy adviser for Doctors Without Borders. Citing the historic example of the drugmakers’ reluctance to provide HIV drugs to poor nations, and even the high price of hepatitis treatments like Sovaldi, she adds, “There’s plenty of examples of pharma companies not doing the right thing.”
What guarantees there will be a problem? The central role of the United States, whose dystopia of a medical bureaucracy is God’s gift to pharmaceutical companies.
Every other country in the world has a three-stage process for approving and pricing prescription drugs. Governments first ask if the drug is safe. If the answer is yes, it asks if the drug is effective.
If the drug passes those two hurdles, most governments then ask how much more effective the new drug is compared to existing medicines. This efficacy calculation becomes the starting point for price negotiations, which usually involve threatening to keep the drug out of the country’s state-insured pool of medications if the company does not come up with a reasonable price.
The U.S. either skips or botches these steps. First, there is no regulatory review that determines comparative efficacy. In the U.S., the FDA review ends after the first two steps: Once a drug is deemed safe and effective, it goes on the market.
Then comes the whopper: All FDA-approved drugs must, by law, be covered by Medicaid. This rule dates to 1990 with the creation of the Medicaid Drug Rebate Program. The “grand bargain” that was supposed to be built into this reform concept was that all FDA drugs would be purchased by Medicaid, provided that manufacturers gave the government either the best price available to insurers, or a 23.1 percent discount over the drug’s list price.
This sounds great, except drug manufacturers simply began figuring the Medicaid “discount” into their list-price calculations. If the medical condition is serious enough and the drug has no effective analog, companies can dictate their price. As a result, we end up with situations like the 2014 Sovaldi episode, in which Medicaid spent $3 billion in a single year just on the one drug, and was still forced to severely ration the medicine, giving it to just 2.4 percent of hepatitis-C patients. Gill notes that only 37 percent of Americans are treated for hepatitis C even now, in part because of the high price of the drug.
The business model for Big Pharma is brilliant. A substantial portion of research and development for new drugs is funded by the state, which then punts its intellectual work to private companies, who are then allowed to extract maximum profits back from the same government, which has over decades formalized an elaborate process of negotiating against itself in these matters.
How big are these giveaways? Since the 1930s, the NIH has spent about $930 billion in research. Between 2010 and 2016, every single drug that won approval from the FDA — 210 different pharmaceuticals — grew at least in part out of research funded by the NIH. A common pattern involves R&D conducted by a small or midsize company, which sells out to a behemoth like Gilead the instant its drug makes it through trials, and obscene prices are set.
This was the case with Sovaldi, for instance, which Gilead acquired when it spent $11 billion in 2012 buying out original developer Pharmasset, which had worked on a line of hepatitis drugs. Within five years, Gilead earned more than $58 billion on a line of hepatitis treatments it won in the Pharmasset deal.
This same pattern seems likely to hold with Covid-19 treatments, only the cycle of exploitation will be accelerated. “It’s a microcosm of a larger broken system, in which you have an R&D system that’s profit-driven rather than people-driven,” says Gill. “These problems existed before Covid-19, and now the U.S. is pumping billions of taxpayer funds into these companies, in most cases with no strings attached.”
Those billions are going to a handful of pharmaceutical companies participating in the Trump administration’s Operation Warp Speed, the stated aim of which is to deliver 300 million doses of Covid-19 vaccine by January 2021. On March 30th, the Department of Health and Human Services announced $456 million in spending for a Johnson & Johnson vaccine program. On April 16th, it announced $483 million for Moderna, a company that (this is not a joke) has never once successfully brought a drug to market. AstraZeneca got $1.2 billion for its vaccine program on May 21st. On June 1st, Emergent BioSolutions won $628 million to provide manufacturing for vaccines. On July 7th, Novavax cashed in, with $1.6 billion for vaccine development. Toward the end of July, the Trump administration announced a deal with Pfizer and the German firm BioNTech to spend $2 billion on 100 million doses of a vaccine. One of these companies is likely to develop the drug that allows the world to go back to normal, and the heroism of those researchers is going to be overshadowed by a profiteering system that rewards their bosses instead of them.
Indeed, the Pfizer deal surprised some, because it seemed to be priced at just $19.50 per dose. But experts estimate that when all is said and done, the same drug will sell overseas for about half that cost. As one Democratic Hill staffer puts it, “They’re making sure that the U.S. pays the highest possible price.”
The Trump administration has tools at its disposal that it could use to lower prices. The Bayh-Dole Act of 1980 gives any agency that funds research leading to a patent to use “march-in rights” to give out licenses to other manufacturers, if, among other things, the patent holder has not done enough to meet the “health or safety needs” of consumers. The president could also employ a federal law called Section 1498, which essentially allows the government to ignore patent rights in an effort to lower prices. Such rights have been invoked before, such as when Bayer cut prices of the anti-anthrax drug ciprofloxacin after the Bush II administration threatened to use that authority (ironically, current Trump HHS Secretary Alex Azar worked under Bush during that time).
“Taxpayers are the angel investors in pharmaceuticals,” says Doggett. “Any other investor would demand a stake in the outcome.”
To date, Trump has shown no interest in invoking either power. He recently signed four related executive orders that ostensibly would lower prices of generics through several means, including allowing importation from Canada and forcing Medicaid to buy drugs at the same prices that other countries pay. One Democratic aide called it “interesting” — but it was amusing to hear Pfizer CEO Albert Bourla complain that Trump was ushering in “socialized medicine.”
The casual follower of this story is probably best served understanding the Covid-19 crisis less as a historic boondoggle (that’s more likely to be found in the financial bailouts) and more as an all-out war by industry lobbyists to retain a system that is already sociopathic and grotesquely anti-competitive in the face of intense public pressure during the pandemic. To be sure, companies like AstraZeneca and Pfizer will end up making a giant pile of money from vaccines and therapies. This is particularly the case because of the somewhat eccentric nature of the disease.
“We might need several vaccines,” says Whitrap, echoing a sentiment suggested by numerous scientists, that the best course ultimately might be a cocktail of different antibody-producing techniques that will have to be administered in an overlapping strategy, perhaps with regular booster shots.
Add the fact that treatment of the already-infected will involve combination therapies (like remdesivir with dexamethasone, to begin with), and the endgame for pharmaceutical companies might be years if not decades of doses that will have to be stockpiled in enormous quantities everywhere on Earth.
This will be worth many billions to firms like Gilead, but the more important win for these companies is staving off efforts to end the monster-subsidy system built into the grant-to-patent process that is suddenly in plain view because of this disaster.
The early days of the pandemic provided ominous clues on these fronts. In March, Gilead had the stones to apply for an “orphan” designation for remdesivir, which would have given it a seven-year exclusivity window, tax breaks, waived FDA fees, and other commercial advantages.
The orphan designation was created in 1983 to provide an incentive for drug companies to develop treatments for rare disorders that affect comparatively small numbers of people, like Wilson’s disease or familial hypercholesterolemia — horrific diseases that are a major challenge to treat, but don’t offer drug companies a potential significant windfall if they develop a cure. Under the law, companies can earn orphan designation for a drug if it’s intended for treatment of fewer than 200,000 Americans.
Gilead applied for orphan perks before there were 200,000 sufferers of Covid-19 in the United States, but everyone knew this was no rare disease. Such a brazen effort to try to get the government to hand over tax credits and help squeeze out generic competitors through the use of a law designed to bribe pharmaceutical firms into developing cures for financially unpromising diseases was crude, but effective. The FDA granted the request! (Gilead did not respond to requests for comments on this story.)
Public Citizen called the move “outrageous,” and so did Bernie Sanders (well, Bernie said “truly outrageous”), and there was enough of a backlash that Gilead rescinded its own request on March 25th.
The Gilead orphan example, however, was indicative not only of the pharmaceutical companies’ thinking, but also of the political climate. Big Pharma has been extraordinarily adept at lobbying and keeping effective control of Congress. In 2003, Congress passed the Medicare Prescription Drug act, a bill pitched as a way to reduce drug prices that became a titanic industry handout.
The Bush-era law included a notorious anti-competitive provision barring the government from using its purchasing power to negotiate with companies. Much of the bill was written by Louisiana Rep. Billy Tauzin, who retired from the House shortly after it was passed and took a $2 million-per-year Thank You for Smoking-style plum job from the trade group PhRMA as the drugmakers’ Spokesperson for Evil.
A few years later, when a popular young politician named Barack Obama ran for president and won the White House promising to lower drug prices through reimportation and bulk negotiation, Tauzin and his crew met repeatedly with the new leader. At the conclusion of those meetings, the Obama administration took those proposed reforms off the table.
“The pharmaceutical companies are clearly nondiscriminatory in the political sense,” says Doggett. “Their political power is incredible.”
In March, we saw a dramatic demonstration, when the first $8.3 billion emergency-spending bill made its way through Congress. The bill included a provision inserted by Democrats that would have limited the intellectual-property rights of companies developing vaccines the government thinks are priced unfairly. Industry lobbyists not only managed to kill that provision, they also got another one inserted that protected the industry from having the approval of drugs delayed if the product is overpriced. “They couldn’t even hold off those two clauses,” Posner says.
For Posner, who has written extensively about Big Pharma, the spectacle of Democrats pounding the table for an end to price gouging is more like Kabuki theater. A few scattered members, like Doggett, will make elaborate demands, but in bills that have no hope of passing. Meanwhile, pharmaceutical companies always seem to get what they want. Posner points to the swine flu vaccine in the Gerald Ford years, when companies like Sharp and Dohme (Merck) refused to help develop vaccines unless they were guaranteed profits and shielded from liability.
Ultimately, the swine flu vaccine was a fiasco, resulting in a number of horrible side effects, including as many as 450 cases of the degenerative nerve disease Guillain-Barré. The taxpayer ended up paying for the swine flu vaccine coming and going, through guaranteed profits at the front and outlays for piles of lawsuits from victims on the other side. Nothing like that has happened with Covid-19, but the same pattern of major concessions won upfront, mixed with what amounts to guarantees of profit, is present.
“It’s a rip-off,” says Posner, comparing the olive-branch “no profit” promises by vaccine-makers to the free samples handed out by heroin dealers. In the lifesaving drug business, once you’re in the door, the rest is just counting money. And with Covid-19, the counting has already begun.

|
|
Progressive People's Convention Starts Today |
|
|
Written by <a href="index.php?option=com_comprofiler&task=userProfile&user=55705"><span class="small">Progressive Democrats of America, Reader Supported News</span></a>
|
|
Sunday, 16 August 2020 08:18 |
|
Excerpt: "We invite all Americans, and indeed the people of the world, to attend Progressive Central 2020 to hear a powerful vision for a prosperous, just, and sustainable America."
Senator Kamala Harris. (photo: Irfan Khan/Getty Images)

Progressive People's Convention Starts Today
By Progressive Democrats of America, Reader Supported News
16 August 20
Progressives to hold Progressive Central -- “The People’s Convention” -- during the Democratic Convention next week
lan Minsky, Executive Director of Progressive Democrats of America (PDA), says "Progressive Central will give voice to many of the leading left-progressive in the United States. We have an impressive list of speakers, whose thoughts about American society will resonate across the entire population.
"Let's be honest. The Democratic Party is split into two factions - and the progressive wing is ascendent. The core principles and policies of Progressive Democrats address the needs of the American people better than any other political formation in the country. This was true before the
COVID-19 public health and economic crises, and it's even more true now. Just as the progressive left lifted the country out of the Great Depression, we have the policies that suit the moment.
"Let's also be perfectly clear, Progressive Central 2020 is convened in the spirit of a unified front to defeat Donald Trump in December. We believe that giving full voice to the Progressive wing of the Democratic Party is the best strategy to achieve that end: to elect Joe Biden and Kamala Harris, take back the Senate, expand the House Majority and win State Houses across the country.
We invite all Americans, and indeed the people of the world, to attend Progressive Central 2020 to hear a powerful vision for a prosperous, just, and sustainable America."
See below for full Progressive Central 2020 schedule, or click here:
https://pdamerica.org/progressive-central-2020-schedule/
The panels are free and open to the public. People must register in advance at this link: https://zoom.us/meeting/register/tJ0vfuiqqzgtH938wOFfTDNMyzd1yWZP6drC
Progressive Democrats of America is a grassroots political action committee founded in 2004 to transform the Democratic Party and U.S. politics by working inside and outside of the party; by working to elect empowered progressives; and by building the progressive movement in solidarity with peace, justice, civil rights, environmental, and other reform efforts.
For more information about PDA, please see www.PDAmerica.org
2020 Progressive Central schedule:
Sunday: Aug 16th - 3:00 pm - 5:00 east
3pm - Opening - Progressives and the current Democratic Convention
Host/Moderator - Alan Minsky
Panelist - Jeff Cohen, Paco Fabian, Sen. Nina Turner, Judith Whitmer, Kai Newkirk, Zenaida Huerta (invited)
4pm -
Healthcare - Medicare For All
Host/Moderator - Dr Bill Honigman
Panelist - Donna Smith, Dr. Paul Song, Amirah Sequeira NNU, Rose Roach Minnesota Nurses, Sen. Vincent Fort
****************
Monday: Aug 17th 3:00 pm - 5:00 east
3pm -
Elections - The Fight to Protect our Democracy
Host/Moderator - Mimi Kennedy
Panelist - Bennie Smith, Greg Palast, Andrea Miller (invited)
4pm -
The Struggle for Racial Justice in 21st Century America
Host/Moderator - Rodney Sadler
Panelist - Rep, Barbara Lee, Cheryle Renee Moses, Donald Whitehead, Colette Alston, Dr. Willie Keaton, Joel Segal
****************
Tuesday: Aug 18th 3:00 pm - 5:00 east
3pm
- Foreign Policy
- Forging a New Peace Policy - Ending Never Ending Wars
Host/Moderator - Alan Minsky
Panelist - Medea Benjamin, Phyllis Bennis, Norman Solomon, Dennis Kucinich, Rep. Ro Khanna
4pm
- Immigration
- Trump's Racist Immigration Policy - Deportations, ICE, DACA
Host / Moderator - Patti Serrano
Questions in chat - Dan O'Neal
Panelist - Erika Andiola , Ray Ybarra Maldonado, Jose Alejandro la Luz, Rep Chuy Garcia, Rep. Raul Grijalva (health permitting)
**************
Wednesday: Aug 19th 3:00 pm - 5:00 east
3pm -
Student Debt
Host/Moderator - Meleiza Figueroa
Panelist - Professor Chris Newfield, Representative from the Debt Collective, Rep. Ilhan Omar (invited), Student Debt Holder testimonies
4pm -
Climate Emergency
Host/Moderator - Russell Greene
Panelist - Anthony Rogers Wright CJA, Rev. Lennox Yearwood, panel still in formation
********************
Thursday: Aug 20th - 3:00 pm - 5:00 east
3pm -
Economics/Labor
Host/Moderator - Alan Minsky
Panelist - Stephanie Kelton, William Darity, Jr.,
Joseph Geevarghese Our Revolution, Michael Dimondstein USPS workers union, Clem Balanoff Transit Workers Union, Carl Rosen Electrical Workers (invited), Rev. William Barber (invited)
4pm -
Closing - Progressives & COVID-19 Policy
Host/Moderator – Alan Minsky
Panelist - Michael Lighty, Bill Fletcher Jr, Senator Nina Turner, possibly Jesse Jackson with John Nichols by video, Representative from CPCC (invited)
Plus short videos and statements from Progressive Congresspeople and Candidates throughout
Check here for ongoing updates to the schedule:
https://pdamerica.org/progressive-central-2020-schedule/

|
|